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Conclusions: In serial DW-MRI for rectal cancer treatment response 
evaluation, a repeatability coefficient of 10% has to be considered to 
account for measurement variations. These variations represent 
observer judgement and patient and MR spectrometer induced 
changes.  
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Purpose/Objective: After radiotherapy treatment a tumor residue 
may remain in the patient, hence showing FDG uptake. If the overlap 
between this active region and the FDG-uptake area before treatment 
is high, it might be an indication that the dose delivered was not 
sufficient to eradicate the tumor. The purpose of this study is to 
compare the overlap fractions of high FDG uptake areas before and 
after treatment when the image registration between the two stages 
is performed using a rigid rotation-translation or using a deformable 
registration algorithm. 
Materials and Methods: For 18 non-small cell lung cancer (NSCLC) 
patients, two co-registered CT-PET image datasets were available: 
one scanned before (chemo-)radiotherapy (pre-RT); and one scanned 
3 months after treatment (post-RT). First, a rigid registration of the 
CT datasets was performed; then a volume of interest (VOI) was 
created based on the PTV, with a 2 cm margin expansion. After this, a 
deformable registration of the pre-RT CT scan to the post-RT CT scan 
was performed using the Demons algorithm. The deformation fields 
resulting from rigid and non-rigid registrations of the CT scan were 
then applied to the PET scan. 
The overlap fractions (OF) between the 34%, 40%, 50% and 60% of 
SUVmax high uptake areas in the original and deformed pre-RT scan and 
the 70% of SUVmax high uptake areas (as a surrogate for tumor residue) 
in the post-RT scan were finally calculated according to the following 
definition: OF = (overlapping area/smallest volume). 
Results: After deformable registration of the pre-RT PET scan, the 
overlap fractions (mean±1SD) of the 34%, 40%, 50% and 60% of SUVmax 
high uptake areas with the 70% of SUVmax high uptake area in the post-
RT scan increased from (67±34)%, (58±33)%, (45±32)%, (37±31)%, 
(29±30)% to (78±35)%, (74±35)%,(65±31)%, (54±31)% and (49±31)% 
respectively. These values are shown in figure1. 
 
 
Conclusions: In the deformed pre-RT PET-scan higher overlap 
fractions were reported compared to the non-deformed PET-scan, as 
expected. In the deformed scan the overlap varies from 78% to 49%, in 
the original scan this is 67% to 29%. This data supports the hypothesis 
that the treatment resistant regions are located in the high FDG 
uptake regions prior to treatment. A voxel-by-voxel analysis is 
necessary, and will be part of our future work. 
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Purpose/Objective: The outcome of biologic image guided 
radiotherapy depends on the definition of the biologic target. Studies 
have indicated that both metabolism and perfusion may be relevant 
targets for such dose escalation approaches. The purpose of the 
current work was to segment images derived from dynamic 18FDG-PET 
into perfusion and metabolic target regions. Furthermore, to study 
the dose distributions in the two targets resulting from dose 
escalation of either the metabolic or perfusion region. 
Materials and Methods: Eleven patients with soft tissue sarcomas 
were investigated with dynamic FDG-PET. The images were analyzed 
voxel-by-voxel using a two compartment model, and estimates of 
perfusion and the metabolic rate where produced as parameter maps. 
The two image series where segmented using Otsu’s method and 
exported to a treatment planning system (Oncentra Masterplan v4.1, 
Nucletron, the Netherlands). Two biological target volumes were 
defined from respective maps, BTVper and BTVmet, and Dice similarity 
coefficient was used to compare them. In addition the planning target 
volume (PTV) was generated from the gross tumor while excluding the 
respective BTV. A seven field IMRT was set up for a dose painting by 
contours regime, where PTV was planned for 60Gy and 70Gy to either 
BTV. Thus, two separate plans were created for each patient with 
dose escalation of either BTVper or BTVmet. 
Results: The volume of BTVper and BTVmet was 209 ± 170 cm3 and 243 ± 
147 cm3, respectively, while Dice coefficient for the two BTVs was 
0.75 ± 0.13 (population-based mean and s.d.). For each patient, the 
resulting dose volume histograms (DVHs) of the PTV, BTVper or BTVmet 
were compared for both plans. For the plan where BTVper is dose 
escalated, significant differences were found between DVHs of BTVper 
and BTVmet. For instance, D98 was significantly lower in BTVmet. The 
resulting mean dose in BTVmet was 67 ± 3.2 Gy. For the plan where 
BTVmet is dose escalated, there were smaller differences between the 
DVHs. The mean dose in BTVper was in this case 68 ±1.7 Gy. The mean 
dose in the boost target volume was for both instances 69 ± 1.0 Gy. 
Conclusions: In summary; dose escalation of one of the BTVs results in 
a partial dose escalation of the other BTV, though coverage was not 
always complete in the latter region. For the patients in question 
BTVmet covered on average a larger region than BTVper. Thus, boosting 
the metabolic region may offer better coverage of aggressive tumor 
regions. However, if tumor aggressiveness is equally pronounced in 
the two regions, this should be taken into account in the treatment 
planning.  
   
 
 
